Skip to main content
. Author manuscript; available in PMC: 2020 Jun 27.
Published in final edited form as: J Med Chem. 2019 Jun 12;62(12):5810–5831. doi: 10.1021/acs.jmedchem.9b00136

Figure 9. Ex vivo antiviral activity of 21b and 8g in human primary dendritic cells.

Figure 9.

Dose response of DENV infection (blue) and cell viability (black) to compounds 21b (A) and 8g (B) measured by plaque assays and alamarBlue assays, respectively, 72 hours after infection of primary human monocyte-derived dendritic cells (MDDCs). Shown is a representative experiment with cells from a single donor, out of 2 independent experiments conducted with cells derived from 2 donors, each with 6 biological replicates; shown are means ± SD.